uMotif welcome Andrew McDonagh as Chief Technology Officer
uMotif investing in top software development talent to build the technology platform putting patients at the centre of clinical research.
London, UK – September 4, 2018 - uMotif are pleased to announce the appointment of Andrew McDonagh as Chief Technology Officer. Andrew will be responsible for overseeing the development of the uMotif technology platform.
"Andrew joining the team is a real coup for uMotif. His rare combination of knowledge, experience and track record of delivering software platforms in a regulated environment will accelerate the ongoing development of the uMotif technology suite. We are bringing a patient-centric approach to clinical trials and Andrew will be instrumental in making this happen." said Bruce Hellman, uMotif CEO and co-founder.
McDonagh brings over 20 years of software development success to the role and joins uMotif having spent three years at AstraZeneca, where he led internal Application Lifecycle Services that provided software development, testing, and automation services. Prior to AstraZeneca, Andrew was responsible for software engineering and product development of the Medidata Edge CTMS (Clinical Trial Management System).
McDonagh said “I'm delighted to be joining a company on an amazing path to disrupt clinical research with an innovative and patient-centric approach. It's great to be part of a company helping patients to more easily and accurately record details of their symptoms and experience, which in turn powers clinical researchers to obtain the data quality and quantity they need for today's therapeutic discoveries."